tbuckley/cabot-search huggingface dataset:
Kidney dysfunction and nephromegaly related to kidney Aichi virus infection
Authors: Dorann Bartebin, David Buob, Nicolas Veyrenche, Jacques Fourgeaud, Pierre Frange, Bénédicte Neven, Cyrielle Aveline, Benjamin Thoreau, Nicolas Gauthier, David Boutboul, Khalil El Karoui
Journal: Kidney International (2025)
Phase I study of induction chemotherapy followed by intensity-modulated radiation therapy (IMRT), accelerated fractionation (AF), simultaneous integrated boost (SIB), and concomitant high dose cisplatin for locally-advanced head and neck cancer (LAHNC)
Authors: L. E. Feldman, M. Agulnik, J. Salama, R. Ortiz, M. Yao, K. Pytynia, J. B. Epstein, D. Reisberg, A. Minn, A. Mundt
Journal: Journal of Clinical Oncology (2008)

6073 Background: Newer chemotherapic strategies and radiation therapy technologies are rapidly gaining acceptance as standard treatment for patients with LAHNC. However, sequential induction chemotherapy followed by IMRT/AF/SIB in combination with concurrent high dose cisplatin has here-to-fore had little formal testing in clinical trials. Therefore, we tested the feasibility of this sequential approach in a phase I dose escalation design to determine the maximum tolerated dose (MTD) of cisplatin. Methods: Eligible patients (pts) had previously untreated, pathologically confirmed, squamous cell carcinoma, either stage III or IV LAHNC, ECOG PS <2, adequate organ function, and radiological evidence of disease. Induction TPF (docetaxel 75 mg/m2, cisplatin 75–100 mg/m2, and 5-FU 750–1000 mg/m2) chemotherapy was given q 3 weeks for 2 cycles. Radiotherapy was then given over 30 fractions in 6 weeks and consisted of simultaneous delivery of 2.2 Gy/fraction to gross tumor and pathologically involved lymph nodes, 2.0 Gy/fraction to regions at high risk for subclinical disease, and 1.8 Gy/fraction was delivered to areas at risk for microscopic disease. Concurrent cisplatin was administered on d 1 and d 22. The initial patient cohort received a dose of 80 mg/m2 and escalated by 10 mg/m2 at each dose level to a maximum dose of 100 mg/m2. Results: Twelve patients were enrolled. Baseline data include: M:F= 8:4, median age 58 (range of 49–74), PS 0:1= 8:4. The site of primary disease was oropharynx (6), oral cavity (3), larynx (2), and hypopharynx (1). One patient at dose level 3 (100mg/m2) experienced a grade 4 cardiac toxicity (troponin leak). The MTD was defined as 100mg/m2 as 5/6 patients at this dose level did not experience a DLT. Sixty-four percent of the pts required gastrostomy tube placement. Seventy-three percent of pts had a complete remission (CR), 18% had a partial remission (PR), 9% had stable disease (SD). Conclusions: Induction chemotherapy followed by concomitant high dose cisplatin (100 mg/m2) and IMRT/AF/SIB is feasible. Based on these findings a phase II clinical trial with this MTD of cisplatin is planned. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration sanofi-aventis
Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association
Authors: Thomas D. Ryan, James E. Bates, Karen E. Kinahan, Kasey J. Leger, Daniel A. Mulrooney, Hari K. Narayan, Kirsten Ness, Tochukwu M. Okwuosa, Nino C. Rainusso, Julia Steinberger, Saro H. Armenian
Journal: Circulation (2025)

The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovascular disease in patients with cancer and survivors. There is increasing recognition that nearly all cancer treatments pose some short- or long-term risk for development of cardiovascular disease and that pediatric patients with cancer may be especially vulnerable to cardiovascular disease because of young age at treatment and expected long life span afterward. Anthracycline chemotherapy and chest-directed radiotherapy are the most well-studied cardiotoxic therapies, and dose reduction, use of cardioprotection for anthracyclines, and modern radiotherapy approaches have contributed to improved cardiovascular outcomes for survivors. Newer treatments such as small-molecule inhibitors, antibody-based cytotoxic therapy, and immunotherapy have expanded options for previously difficult-to-treat cancers but have also revealed new cardiotoxic profiles. Application of effective surveillance strategies in patients with cancer and survivors has been a focus of practitioners and researchers, whereas the prevention and treatment of extant cardiovascular disease is still developing. Incorporation of new strategies in an equitable manner and appropriate transition from pediatric to adult care will greatly influence long-term health-related outcomes in the growing population of childhood cancer survivors at risk for cardiovascular disease.
CDH17-targeting CAR-NK cells synergize with CD47 blockade for potent suppression of gastrointestinal cancers
Authors: Liuhai Zheng, Youbing Ding, Xiaolong Xu, Huifang Wang, Guangwei Shi, Yang Li, Yuanqiao He, Yue Gong, Xiaodong Zhang, Jinxi Wei, Zhiyu Dong, Jiexuan Li, Shanchao Zhao, Rui Hou, Wei Zhang, Jigang Wang, Zhijie Li
Journal: Acta Pharmaceutica Sinica B (2025)
Monitoring Acidification Preceding Aβ Deposition in Alzheimer's Disease
Authors: Guannan Zhu, Hong Zhang, Ruoxi Xie, Muhammad Rizwan Younis, Shengxiang Fu, Xiaoze Wang, Beibei Liu, Kun Li, Su Lui, Min Wu
Journal: Advanced Healthcare Materials (2025)

Abstract Amyloid beta (Aβ) is the primary early biomarker of Alzheimer's disease (AD), and since an acidic environment promotes Aβ aggregation, acidification plays a crucial role in AD progression. In this study, a novel acid‐responsive near‐infrared (NIR) fluorescent probe alongside multiple molecular biology techniques to investigate the temporal relationship between acidification and Aβ deposition, as well as the underlying mechanisms of acidification is employed. By monitoring 2‐ to 11‐month‐old APP/PS1 mice and wild‐type (WT) mice, it is detected significant fluorescence signal in APP/PS1 mice beginning at 3 months preceding Aβ deposition at 5 months, and peaking at 5 months, followed by cognitive deficits at 8 months. Additionally, elevated monocarboxylate transporter 4 (MCT4) protein expression in 3‐month‐old APP/PS1 mice indicated disruption of astrocyte‐neuron lactate shuttle (ANLS) homeostasis. Overall, this findings first demonstrate that acidification precedes Aβ deposition, peaks at the onset of Aβ deposition, and diminishes thereafter, with early acidification likely driven by the disruption of ANLS.
Self‐Nourishing and Armored Probiotics via Egg‐Inspired Encapsulation
Authors: Sohyeon Park, Sungwon Jung, Geonhui Lee, Erin Lee, Rodger Black, Jinkee Hong, Sangmoo Jeong
Journal: Advanced Healthcare Materials (2025)

Abstract The gut microbiota plays an essential role in regulating overall physiology, including metabolism and neurological and immune functions. Therefore, their dysregulation is closely associated with metabolic disorders, such as obesity and diabetes, as well as other pathological conditions, including inflammatory bowel diseases, cancer, and neurological disorders. Probiotics are commonly used to maintain a healthy gut microbiome, but their oral delivery is inefficient mainly due to their poor stability in the harsh gastrointestinal (GI) environment. This work presents an innovative encapsulation strategy, inspired by the natural structure of an egg, for the effective oral delivery of probiotics, termed PIE (Probiotics‐In‐Egg). The PIE technology is based upon encapsulating probiotics with phosvitin and ovalbumin derived from egg yolk and egg white, respectively. PIE exhibits significantly enhanced survival and proliferation in a simulated GI tract, as well as the ability to neutralize harmful reactive oxygen species (ROS) and sustain in nutrient‐depleted conditions. Moreover, when administered orally in mouse models, PIE demonstrates excellent bioavailability and enhanced colonization in the GI tract. This egg‐inspired encapsulation technology has great potential as a practical and effective platform for oral delivery of probiotics, which can significantly help maintain a healthy gut microbiome.
Enhanced cGAS‐STING Activation and Immune Response by LPDAM Platform‐Based Lapachone–Chemical–Photothermal Synergistic Therapy for Colorectal Cancer
Authors: Xiaoyu Pan, Yan Lin, Chunlin Lin, Songyi Liu, Penghang Lin, Xiang Lin, Ruofan He, ZiChen Ye, Jianxin Ye, Guangwei Zhu
Journal: Advanced Healthcare Materials (2025)

Abstract The cGAS‐STING signaling pathway is a pivotal immune response mechanism that bridges tumor and immune cell interactions. This study describes a multifunctional LPDAM nanoplatform integrating Lapachone, polydopamine (PDA), and Mn 2+ , which synergistically kills tumor cells and activates the cGAS‐STING pathway, thereby inducing DC maturation and T cell activation to achieve potent antitumor immunity. In the tumor microenvironment, Lapachone generates H 2 O 2 via the NAD(P)H:quinone oxidoreductase 1 (NQO1 enzyme), while Mn 2+ catalyze H 2 O 2 conversion into •OH through chemodynamic effects (CDT). The photothermal effects (PTT) of PDA further amplify this cascade reaction, producing reactive oxygen species (ROS) that damage tumor mitochondria and release mitochondrial DNA (mtDNA). The released mtDNA activates the cGAS‐STING pathway, while Mn 2+ enhances the sensitivity of cGAS to mtDNA, leading to robust antitumor immunity. Concurrently, photothermal‐induced immunogenic cell death (ICD) promotes d endritic cells ( DCs) maturation, further strengthening immune responses. Moreover, Mn 2 ⁺ also serves as a contrast agent for T1‐weighted magnetic resonance imaging (MRI), offering precise tumor visualization. This study demonstrates that the LPDAM nanoplatform facilitates Lapachone/CDT/PTT synergistic therapy under MRI guidance, showcasing its potential as an innovative strategy for combined immunotherapy in clinical oncology.
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1
Authors: Saadettin Kilickap, Ana Baramidze, Ahmet Sezer, Mustafa Özgüroğlu, Mahmut Gumus, Igor Bondarenko, Miranda Gogishvili, Marina Nechaeva, Michael Schenker, Irfan Cicin, Ho Gwo Fuang, Yaroslav Kulyaba, Kasimova Zyuhal, Roxana-Ioana Scheusan, Marina Chiara Garassino, Yuntong Li, Cong Zhu, Manika Kaul, Javier Perez, Frank Seebach, Israel Lowy, Jean-Francois Pouliot, Eric Kim, Heather Magnan
Journal: Journal of Thoracic Oncology (2025)
Tailoring Lipid Nanoparticle with Ex Situ Incorporated Conjugated Oligoelectrolyte for Enhanced mRNA Delivery Efficiency
Authors: Wilson Wee Mia Soh, Esteban Finol, Samuel J. W. Chan, Ji‐Yu Zhu, Sebastian Sean Jing Kang Liau, Ava Bier, Eng Eong Ooi, Guillermo C. Bazan
Journal: Advanced Healthcare Materials (2025)

Abstract Developing new lipid nanoparticle (LNP) formulations typically involves reconstruction from separate elements followed by rigorous purification steps, contributing to drawn‐out drug discovery processes. Membrane‐intercalating conjugated oligoelectrolytes (COEs) are water‐soluble molecules featuring a conjugated backbone and peripheral ionic groups, specifically designed to spontaneously integrate into lipid bilayers. Herein, an ex situ strategy to “dope” the representative COE‐S6 into pre‐formed messenger RNA‐LNPs (mRNA‐LNPs) is presented, exploiting its spontaneous membrane intercalation property through a straightforward add‐and‐mix procedure. Incorporating 0.2% COE‐S6 into mRNA‐LNPs relative to lipid content reduced particle size from 84.5 ± 1 to 67.9 ± 0.8 nm, elevated cellular uptake, and improved endosomal escape. These traits culminate in an increase in in cellula transfection from 24.2 ± 1.6% to 98.7 ± 0.6%. When injected intravenously into healthy BALB/c mice, the optimized COE‐S6‐doped mRNA‐LNPs boost in vivo luciferase expression by 1.75‐fold. Additionally, COE‐S6‐doped mRNA‐LNPs exhibit fluorogenic properties, enabling intracellular mechanistic studies via confocal microscopy. This simple method enhances the properties of mRNA‐LNPs with minimal COE quantities, offering a novel strategy to improve existing LNP formulations and provide optical reporting capabilities, essential for expediting drug discovery and delivery.
Comparing Large Language Models for antibiotic prescribing in different clinical scenarios: which perform better?
Authors: Andrea De Vito, Nicholas Geremia, Davide Fiore Bavaro, Susan K Seo, Justin Laracy, Maria Mazzitelli, Andrea Marino, Alberto Enrico Maraolo, Antonio Russo, Agnese Colpani, Michele Bartoletti, Anna Maria Cattelan, Cristina Mussini, Saverio Giuseppe Parisi, Luigi Angelo Vaira, Giuseppe Nunnari, Giordano Madeddu
Journal: Clinical Microbiology and Infection (2025)
Exploring an Innovative Augmentation Strategy in Spinal Fusion: A Novel Selective Prostaglandin EP4 Receptor Agonist as a Potential Osteopromotive Factor to Enhance Lumbar Posterolateral Fusion
Authors: Lisa Findeisen, Xinggui Tian, Corina Vater, Deepak Bushan Raina, Hannes Kern, Julia Bolte, Luisa Straßburger, Lucas-Maximilian Matuszewski, Niels Modler, Robert Gottwald, Anja Winkler, Klaus-Dieter Schaser, Alexander C Disch, Stefan Zwingenberger
Journal: Biomaterials (2025)
A Light‐Activatable Nitric Oxide Donor for Targeted Glaucoma Therapy with Real‐Time Monitoring Capabilities
Authors: Jiamin Liu, Yankun Lu, Yi Tian, Qian Liu, Xinghua Sun, Yi Liu, Yuan Lei
Journal: Advanced Healthcare Materials (2025)

Abstract Primary open‐angle glaucoma (POAG), the most common form of glaucoma, is characterized by a gradual increase in intraocular pressure (IOP). Nitric oxide (NO) donors are promising treatments for POAG, but their effectiveness requires selective NO release triggered by ocular‐relevant stimuli. RhNO‐Ab, a visible light‐activatable NO donor and fluorescent probe is introduced. RhNO‐Ab releases NO from its N‐nitroso group and transforms from a non‐fluorescent spirolactone to fluorescent Rhodamine (Rh) upon NO release. In vitro studies, including in bulk and single molecule level demonstrated a rapid NO release and fluorescence recovery upon light irradiation. Immunofluorescence shows enhanced delivery to target tissues of RhNO‐Ab with ABCA1 antibody modification. Administration of RhNO‐Ab with light at 30, 20, and 10 µ m significantly reduces IOP in NOS3 KO mice by 2.11 mmHg (12.50%, n = 6), 1.77 mmHg (9.88%, n = 6), and 1.55 mmHg (8.23%, n = 6) 3 h post‐treatment ( * p &lt; 0.05). RhNO‐Ab with light also reduces transendothelial electrical resistance (TEER) in Schlemm's canal (SC) endothelial cells (n = 3, * p &lt; 0.05) and upregulates soluble guanylate cyclase (sGC) mRNA and protein expression in mouse outflow tissues and human trabecular meshwork (HTM) cells. Unlike traditional NO donors, RhNO‐Ab offers visible light‐triggered therapeutic NO release and real‐time monitoring, making it a promising novel strategy for POAG treatment.
Loss of tricellular tight junction tricellulin leads to hyposalivation in Sjögren’s syndrome
Authors: Xiangdi Mao, Haibing Li, Sainan Min, Jiazeng Su, Pan Wei, Yan Zhang, Qihua He, Liling Wu, Guangyan Yu, Xin Cong
Journal: International Journal of Oral Science (2025)

Abstract Tricellulin, a key tricellular tight junction (TJ) protein, is essential for maintaining the barrier integrity of acinar epithelia against macromolecular passage in salivary glands. This study aims to explore the role and regulatory mechanism of tricellulin in the development of salivary gland hypofunction in Sjögren’s syndrome (SS). Employing a multifaceted approach involving patient biopsies, non-obese diabetic (NOD) mice as a SS model, salivary gland acinar cell-specific tricellulin conditional knockout ( Tric CKO ) mice, and IFN-γ-stimulated salivary gland epithelial cells, we investigated the role of tricellulin in SS-related hyposalivation. Our data revealed diminished levels of tricellulin in salivary glands of SS patients. Similarly, NOD mice displayed a reduction in tricellulin expression from the onset of the disease, concomitant with hyposecretion and an increase in salivary albumin content. Consistent with these findings, Tric CKO mice exhibited both hyposecretion and leakage of macromolecular tracers when compared to control animals. Mechanistically, the JAK/STAT1/miR-145 axis was identified as mediating the IFN-γ-induced downregulation of tricellulin. Treatment with AT1001, a TJ sealer, ameliorated epithelial barrier dysfunction, restored tricellulin expression, and consequently alleviated hyposalivation in NOD mice. Importantly, treatment with miR-145 antagomir to specifically recover the expression of tricellulin in NOD mice significantly alleviated hyposalivation and macromolecular leakage. Collectively, we identified that tricellulin deficiency in salivary glands contributed to hyposalivation in SS. Our findings highlight tricellulin as a potential therapeutic target for hyposecretion, particularly in the context of reinforcing epithelial barrier function through preventing leakage of macromolecules in salivary glands.
Assessment and Management of Concurrent Substance Use in Patients Receiving Repetitive Transcranial Magnetic Stimulation for Depressive, Obsessive-Compulsive, Psychotic, and Trauma-Related Disorders: A Delphi Consensus Study and Guideline
Authors: Victor M. Tang, Scott Aaronson, Mohamed Abdelghani, Chris Baeken, Tracy Barbour, André R. Brunoni, Samuel Bulteau, Linda L. Carpenter, Paul E. Croarkin, Zafiris J. Daskalakis, Paul B. Fitzgerald, F. Andrew Kozel, Bernard Le Foll, Urvakhsh Meherwan Mehta, Yoshihiro Noda, Frank Padberg, Christian Plewnia, Hang Su, Philip van Eijndhoven, Eric van Exel, Iris van Oostrom, Fidel Vila-Rodriguez, Daphne Voineskos, Saydra Wilson, Daniel M. Blumberger
Journal: American Journal of Psychiatry (2025)

Limited data are available to inform clinicians on how to manage concurrent substance use in the context of repetitive transcranial magnetic stimulation (rTMS) for the treatment of depressive, obsessive-compulsive, psychotic, or trauma-related disorders. The authors convened an international panel of 24 rTMS experts, representative of different geographic regions and subspecialities, and created a consensus guideline for clinicians and researchers on approaches to concurrent substance use in patients receiving rTMS as treatment for primary psychiatric disorders. A Delphi method survey and expert opinion elicited over consecutive rounds of surveys were used, with feedback and discussion after each round. Recommendation statements were established upon very high (≥80%) agreement. Three rounds of surveys and feedback were sufficient to reach a consensus for most topics; where consensus could not be reached, the panel discussed limitations in the current evidence base. Informed by a synthesis of the literature and practice-based evidence, the expert panel provides several consensus recommendations on the topics of screening, monitoring, risk assessment, and mitigation associated with various degrees of substance use, and specific considerations for alcohol, cannabis, stimulants, and opioids. Instead of excluding all people who use substances, a nuanced approach should be taken based on an assessment of risk factors for clinical instability and severity of use. The most important safety risk with substance use is the presence of intoxication or withdrawal states, with the most data supporting seizure risk in unstable alcohol or nonmedical stimulant use. Although there is no evidence of reduced rTMS efficacy for a psychiatric disorder in the presence of concurrent substance use, the lack of data in this area warrants caution. These recommendations can be readily implemented clinically and provide a framework for future research. In patients receiving rTMS for a primary psychiatric disorder, assessment and management of co-occurring substance use is complex, requiring greater attention, standardization, and further study.
A Randomized Clinical Trial of Prolonged Exposure Therapy With and Without Topiramate for Comorbid PTSD and Alcohol Use Disorder
Authors: Sonya B. Norman, Matthew T. Luciano, Kaitlyn E. Panza, Brittany C. Davis, Michelle Lyons, Brian Martis, Scott C. Matthews, Abigail C. Angkaw, Moira Haller, Katharine Lacefield, Arthur L. Brody, Paula P. Schnurr, Steven L. Batki, Tracy L. Simpson, Robert M. Anthenelli
Journal: American Journal of Psychiatry (2025)

Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) frequently co-occur. Prolonged exposure (PE) is an effective treatment for PTSD but shows smaller effects in patients with co-occurring AUD. Topiramate may help reduce alcohol use and PTSD symptoms. This double-blind, placebo-controlled outpatient clinical trial compared 12 sessions of PE plus either topiramate or placebo. One hundred U.S. veterans (mean age=45 years [SD=12], 84% men) with PTSD+AUD were randomly assigned to 16 weeks of treatment with PE+topiramate (up to 250 mg) or PE+placebo to examine effects on alcohol use and PTSD severity at posttreatment assessment and at 3- and 6-month follow-ups. Percent heavy drinking days decreased significantly for both conditions but did not differ between groups. PTSD scores were lower in the PE+topiramate group than in the PE+placebo group at posttreatment assessment, but not at follow-ups. The same patterns were observed for loss of PTSD diagnosis and meaningful PTSD symptom change. Change in secondary outcomes (depression, quality of life) did not differ between conditions. PE+topiramate was associated with a greater reduction in PTSD symptoms than PE+placebo during active treatment. The addition of topiramate led to more rapid and pronounced PTSD symptom reduction, which may be of benefit to patients. Because effects of topiramate were not maintained at longer-term follow-up, extending time on topiramate or additional strategies to prolong such effects may be useful. Topiramate did not show added benefit to PE for percent heavy drinking days or secondary outcomes.
Interpretable personalized surgical recommendation with joint consideration of multiple decisional dimensions
Authors: Zhe Du, Zhaoyang Liu, Linru Fu, Che Wang, Zhijing Sun, Lan Zhu, Ke Deng
Journal: npj Digital Medicine (2025)

Surgical planning can be highly complicated and personalized, where a surgeon needs to balance multiple decisional dimensions including surgical effectiveness, risk, cost, and patient's conditions and preferences. Turning to artificial intelligence is a great appeal. This study filled in this gap with Multi-Dimensional Recommendation (MUDI), an interpretable data-driven intelligent system that supported personalized surgical recommendations on both the patient's and the surgeon's side with joint consideration of multiple decisional dimensions. Applied to Pelvic Organ Prolapse, a common female disease with significant impacts on life quality, MUDI stood out from a crowd of competing methods and achieved excellent performance that was comparable to top urogynecologists, with a transparent process that made communications between surgeons and patients easier. Users showed a willingness to accept the recommendations and achieved higher accuracy with the aid of MUDI. Such a success indicated that MUDI had the potential to solve similar challenges in other situations.